Skip to main content
SpringerLink
Log in

Assessment of Femoral Geometric Strength in Osteoporosis Using Hip Structure Analysis

  • Chapter
Osteoporosis in Orthopedics

  • 1064 Accesses

Abstract

Hip structure analysis (HSA) was applied to measure proximal femur geometry and strength using conventional dual-energy X-ray absorptiometry. The structural parameters were cross-sectional area (CSA, index of resistance to forces directed along the long axis), section modulus (index of resistance to bending forces), and buckling ratio (index of cortical stability). HSA has been investigated in racial and gender differences, aging trends, and relations among bone biological makers, body composition, and physical activity and treatment effects by osteoporotic medications. In most of the studies on HSA by antiresorptive drugs (raloxifene, alendronate, risedronate, minodronate, denosumab), the percent change of section modulus was higher than that of bone mineral density (BMD), and the improvements in section modulus are superior in intertrochanter than in femoral neck. On the other hand, teriparatide improved section modulus and BMD; however, the tendency to change in these parameters is different from antiresorptive drugs. The improvement in section modulus was approximately similar in BMD, and the improvement in intertrochanter is not higher than femoral neck. HSA method has some limitations; however, if technological improvements can make them reliable enough for clinical use, geometric measurements may ultimately provide a clearer view of the efficacy of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P, Delmas PD, Ribot C, Sebert JL, Breart G, Meunier PJ for EPIDOS Group (1998) How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 8:247–254

    Article  CAS  PubMed  Google Scholar 

  2. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936

    Article  PubMed  Google Scholar 

  3. Miller PD (2003) Bone mass measurements. Clin Geriatr Med 19:281–297

    Article  PubMed  Google Scholar 

  4. Schuit SCE, van der Klift M, Weel AEAM, de Laet CEDH, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202

    Article  CAS  PubMed  Google Scholar 

  5. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fracture. Arch Intern Med 164:1108–1112

    Article  PubMed  Google Scholar 

  6. Li Z, Meredith MP, Hoseyni MS (2001) A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175–3188

    Article  CAS  PubMed  Google Scholar 

  7. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Dennis M, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289

    Article  CAS  PubMed  Google Scholar 

  8. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10

    Article  CAS  PubMed  Google Scholar 

  9. Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU (1990) Predicting femoral neck strength from bone mineral data: a structural approach. Invest Radiol 25:6–18

    Article  CAS  PubMed  Google Scholar 

  10. Beck TJ, Ruff CB, Scott WW Jr, Plato CC, Tobin JD, Quan CA (1992) Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int 50:24–29

    Article  CAS  PubMed  Google Scholar 

  11. Beck T (2003) Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int 14(Suppl 5):S81–S88

    Article  PubMed  Google Scholar 

  12. Hans D, Duboeuf F, Schott AM, Horn S, Avioli LV, Drezner MK, Meunier PJ (1997) Effects of a new positioner on the precision of hip bone mineral density measurements. J Bone Miner Res 12:1289–1294

    Article  CAS  PubMed  Google Scholar 

  13. Ruff CB, Hayes WC (1983) Cross-sectional geometry of Pecos Pueblo femora and tibiae – a biomechanical investigation. I. Method and general patterns of variation. Am J Phys Anthropol 60:359–381

    Article  CAS  PubMed  Google Scholar 

  14. Melton LJ III, Beck TJ, Amin S, Khosla S, Achenbach SJ, Oberg AL, Riggs BL (2005) Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int 16:460–467

    Article  PubMed  Google Scholar 

  15. Beck TJ, Looker AC, Ruff CB (2000) Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res 15:2297–2304

    Article  CAS  PubMed  Google Scholar 

  16. Nelson DA, Barondess DA, Hendrix SL, Beck TJ (2000) Cross-sectional geometry, bone strength, and bone mass in the proximal femur in black and white postmenopausal women. J Bone Miner Res 15:1992–1997

    Article  CAS  PubMed  Google Scholar 

  17. Takada J, Beck TJ, Iba K, Yamashita T (2007) Structural trends in the aging proximal femur in Japanese postmenopausal women. Bone 41:97–102

    Article  PubMed  Google Scholar 

  18. Khoo BCC, Brown K, Zhu K, Pollock M, Wilson KE, Price RI, Prince RL (2012) Differences in structural geometrical outcomes at the neck of the proximal femur using two-dimensional DXA-derived projection (APEX) and three-dimensional QCT-derived (BIT QCT) techniques. Osteoporos Int 23:1393–1398

    Article  CAS  PubMed  Google Scholar 

  19. Seeman E (2003) Periosteal bone formation – a neglected determinant of bone strength. N Engl J Med 349:320–323

    Article  PubMed  Google Scholar 

  20. Iki M, DongMei N, Tamaki J, Sato Y, Kagamimori S, Kagawa Y, Yoneshima H, for the Japanese Population-based Osteoporosis (JPOS) Study Group (2011) Age-specific reference values of hip geometric indices from a representative sample of the Japanese female population: Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int 22:1987–1996

    Article  CAS  PubMed  Google Scholar 

  21. Committee for Osteoporosis Treatment of The Japanese Orthopaedic Association (2004) Nationwide survey of hip fractures in Japan. J Orthop Sci 9:1–5

    Article  Google Scholar 

  22. Wang XF, Duan Y, Beck TJ, Seeman E (2005) Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone 36:978–986

    Article  PubMed  Google Scholar 

  23. Beck TJ, Ruff CB, Bissessur K (1993) Age-related changes in female femoral neck geometry: implications for bone strength. Calcif Tissue Int 53(Suppl 1):S41–S46

    Article  PubMed  Google Scholar 

  24. Takada J, Iba K, Yoshizaki T, Yamashita T (2012) Correlation between a bone resorption marker and structural geometry of the proximal femur in osteoporotic women treated with raloxifene. J Orthop Surg 20:209–213

    Google Scholar 

  25. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M, Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society (2004) Guidelines for the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 23:97–104

    Article  Google Scholar 

  26. Takada J, Ikeda S, Kusanagi T, Mizuno S, Wada H, Iba K, Sasaki K, Kanaya K, Yoshizaki T, Yamashita T (2014) Evaluation of structural geometry at proximal femur in osteoporotic women treated by eldecalcitol with either raloxifene or bisphosphonate (Japanese). Osteoporos Jpn 22(Suppl 1):338

    Google Scholar 

  27. Beck TJ, Oreskovic TL, Stone KL, Ruff CB, Ensrud K, Nevitt MC, Genant HK, Cummings SR (2001) Structural adaptation to changing skeletal load in the progression toward hip fragility: the study of osteoporotic fractures. J Bone Miner Res 16:1108–1119

    Article  CAS  PubMed  Google Scholar 

  28. Takada J, Iba K, Sasaki K, Kanaya K, Douke T, Yoshizaki T, Yamashita T (2013) Lean mass but not fat mass is associated with hip geometry in Japanese women. BoneKEy 10:s104

    Google Scholar 

  29. Nurzenski MK, Briffa NK, Price RI, Khoo BCC, Devine A, Beck TJ, Prince RL (2007) Geometric indices of bone strength are associated with physical activity and dietary calcium intake in healthy older women. J Bone Miner Res 22:416–424

    Article  PubMed  Google Scholar 

  30. LaCroix AZ, Beck TJ, Cauley JA, Lewis CE, Bassford T, Jackson R, Wu G, Chen Z (2010) Hip structural geometry and incidence of hip fracture in postmenopausal women: what does it add to conventional bone mineral density? Osteoporos Int 21:919–929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17:575–586

    Article  CAS  PubMed  Google Scholar 

  32. Takada J, Miki T, Imanishi Y, Nakatsuka K, Wada H, Naka H, Yoshizaki T, Iba K, Beck TJ, Yamashita T (2010) Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis. J Bone Miner Metab 28:561–567

    Article  CAS  PubMed  Google Scholar 

  33. Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA (2005) Effect of hormone replacement, alendronate, or combination therapy on hip structure geometry: a 3-year, double blind, placebo-controlled clinical trial. J Bone Miner Res 20:1525–1532

    Article  CAS  PubMed  Google Scholar 

  34. Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C (2008) Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 11:351–359

    Article  PubMed  Google Scholar 

  35. Chen Z, Beck TJ, Cauley JA, Lewis CE, LaCroix A, Bassford T, Wu G, Sherrill D, Going S (2008) Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the Women’s Health Initiative hormone intervention trials. J Bone Miner Res 23:1935–1945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Wang H, de Papp AE (2009) DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int 20:911–921

    Article  CAS  PubMed  Google Scholar 

  37. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382–388

    Article  CAS  PubMed  Google Scholar 

  38. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, for the Risedronate Phase III Research Group (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405–413

    Article  CAS  PubMed  Google Scholar 

  39. Takada J, Katahira G, Iba K, Yoshizaki T, Yamashita T (2011) Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis. J Bone Miner Metab 29:458–468

    Article  CAS  PubMed  Google Scholar 

  40. Ito M, Sone T, Fukunaga M (2010) Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. J Bone Miner Metab 28:334–341

    Article  CAS  PubMed  Google Scholar 

  41. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645

    Article  CAS  PubMed  Google Scholar 

  42. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352

    Article  CAS  PubMed  Google Scholar 

  43. Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439–446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M (2011) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) – 02. Curr Med Res Opin 27:1273–1284

    Article  CAS  PubMed  Google Scholar 

  46. Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90:5031–5036

    Article  CAS  PubMed  Google Scholar 

  47. Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures: a randomized, active comparator, double-blind study. Bone 49:605–612

    Article  CAS  PubMed  Google Scholar 

  48. Nakamura T, Takano T, Fukunaga M, Shiraki M, Matsumoto T (2013) Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol. J Bone Miner Metab 31:417–422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rhPTH (1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958

    Article  CAS  PubMed  Google Scholar 

  50. Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106

    Article  CAS  PubMed  Google Scholar 

  51. Sone T, Ito M, Fukunaga M, Tomomitsu T, Sugimoto T, Shiraki M, Yoshimura T, Nakamura T (2014) The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk. Bone 64:75–81

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kitago Orthopaedic Clinic, Kitago, 3-8, 5-33, Shiroishi-ku, Sapporo, 003-0833, Japan

    Junichi Takada M.D., Ph.D.

  2. Department of Orthopaedic Surgery, Sapporo Medical University, Sapporo, Japan

    Junichi Takada M.D., Ph.D.

Authors
  1. Junichi Takada M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junichi Takada M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan

    Yoichi Shimada

  2. Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan

    Naohisa Miyakoshi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Takada, J. (2016). Assessment of Femoral Geometric Strength in Osteoporosis Using Hip Structure Analysis. In: Shimada, Y., Miyakoshi, N. (eds) Osteoporosis in Orthopedics. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55778-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55778-4_4

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55777-7

  • Online ISBN: 978-4-431-55778-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation